Colorectal Cancer: Competitive Landscape to 2026
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Colorectal cancer (CRC) is a cancer that originates in either the colon or the rectum. CRC is the fourth leading cause of mortality among cancer patients in the world, and is the third most diagnosed cancer globally. Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma, and squamous cell carcinoma.
This report provides an assessment of the pipeline, clinical, and commercial landscape of CRC. Overall, GlobalData expects new drug approvals with noval approaches to treatment to drive the CRC market growth over the next decade (2016–2026).
Scope
GlobalData’s Colorectal Cancer: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
Commercial Assessment—leading marketed products, current and future players
Competitive Landscape Analysis—key market events (2016–2026)
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global CRC market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Merck
Bristol-Myers Squibb
Regeneron
Amgen
Boehringer Ingelheim
Bayer
Eli Lilly
Array BioPHarma
Taiho Pharmacuetical
Ono Pharmaceutical
Mologen
Symphogen
Sumitomo Dainippon Pharma
DanDrit Biotech
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Oncology reports